Abstract：
Parkinson\'s disease (PD) is characterized by a prodromal phase preceding the onset of classic motor symptoms. The duration and clinical manifestations of prodromal PD vary widely, indicating underlying heterogeneity within this stage. This discrepancy prompts the question of whether specific factors contribute to the divergent rates of progression in prodromal PD.
This study included prodromal PD patients from the Parkinson\'s progression marker initiative. They were followed up to assess the disease progression. The data collected during the follow-up period were analyzed to identify potential predictors of rapid disease progression in prodromal PD.
In this study, 61 individuals with prodromal PD were enrolled. Among them, 43 patients presented with both RBD and hyposmia, 17 had hyposmia alone, and 1 had RBD alone at baseline. 13 (21.3%) prodromal PD participants exhibited rapid disease progression, with two of these cases advancing to non-neurological diseases. Significant differences were observed between the rapid progression group and no rapid progression group in terms of MDS-UPDRS II score and UPSIT score. Longitudinal analysis showed a significant increase in the MDS-UPDRS III score and MDS-UPDRS total score in the rapid progression group. Regression analyses identified the MDS-UPDRS II score and UPSIT score as predictors of rapid disease progression in prodromal PD.
Our study findings suggest that the MDS-UPDRS II score and UPSIT score may serve as clinical markers associated with rapid disease progression. Further research and development of precise biomarkers and advanced assessment methods are needed to enhance our understanding of prodromal PD and its progression patterns.
This study included prodromal PD patients from the Parkinson\'s progression marker initiative. They were followed up to assess the disease progression. The data collected during the follow-up period were analyzed to identify potential predictors of rapid disease progression in prodromal PD.
In this study, 61 individuals with prodromal PD were enrolled. Among them, 43 patients presented with both RBD and hyposmia, 17 had hyposmia alone, and 1 had RBD alone at baseline. 13 (21.3%) prodromal PD participants exhibited rapid disease progression, with two of these cases advancing to non-neurological diseases. Significant differences were observed between the rapid progression group and no rapid progression group in terms of MDS-UPDRS II score and UPSIT score. Longitudinal analysis showed a significant increase in the MDS-UPDRS III score and MDS-UPDRS total score in the rapid progression group. Regression analyses identified the MDS-UPDRS II score and UPSIT score as predictors of rapid disease progression in prodromal PD.
Our study findings suggest that the MDS-UPDRS II score and UPSIT score may serve as clinical markers associated with rapid disease progression. Further research and development of precise biomarkers and advanced assessment methods are needed to enhance our understanding of prodromal PD and its progression patterns.
摘要：
背景：帕金森病（PD）的特征是在经典运动症状发作之前的前驱阶段。前驱PD的持续时间和临床表现差异很大，表明这一阶段潜在的异质性。这种差异引发了一个问题，即特定因素是否会导致前驱PD的进展速度不同。
方法：本研究包括来自帕金森病进展标志物倡议的前驱PD患者。对他们进行随访以评估疾病进展。对随访期间收集的数据进行分析，以确定前驱PD疾病快速进展的潜在预测因素。
结果：在这项研究中，61例前驱PD患者入组。其中,43例患者同时表现为RBD和低讲症，17人单独患有食欲不振，1例基线时仅有RBD。13名(21.3%)前驱PD参与者表现出快速的疾病进展，其中两个病例发展为非神经系统疾病。在MDS-UPDRSII评分和UPSIT评分方面，快速进展组和非快速进展组之间观察到显着差异。纵向分析显示，在快速进展组中，MDS-UPDRSIII评分和MDS-UPDRS总分显着增加。回归分析确定MDS-UPDRSII评分和UPSIT评分是前驱PD疾病快速进展的预测因子。
结论：我们的研究结果表明，MDS-UPDRSII评分和UPSIT评分可能是与疾病快速进展相关的临床标志物。需要进一步研究和开发精确的生物标志物和先进的评估方法，以增强我们对前驱PD及其进展模式的理解。
方法：本研究包括来自帕金森病进展标志物倡议的前驱PD患者。对他们进行随访以评估疾病进展。对随访期间收集的数据进行分析，以确定前驱PD疾病快速进展的潜在预测因素。
结果：在这项研究中，61例前驱PD患者入组。其中,43例患者同时表现为RBD和低讲症，17人单独患有食欲不振，1例基线时仅有RBD。13名(21.3%)前驱PD参与者表现出快速的疾病进展，其中两个病例发展为非神经系统疾病。在MDS-UPDRSII评分和UPSIT评分方面，快速进展组和非快速进展组之间观察到显着差异。纵向分析显示，在快速进展组中，MDS-UPDRSIII评分和MDS-UPDRS总分显着增加。回归分析确定MDS-UPDRSII评分和UPSIT评分是前驱PD疾病快速进展的预测因子。
结论：我们的研究结果表明，MDS-UPDRSII评分和UPSIT评分可能是与疾病快速进展相关的临床标志物。需要进一步研究和开发精确的生物标志物和先进的评估方法，以增强我们对前驱PD及其进展模式的理解。
